JAMA Otolaryngol Head Neck Surg: 鼻塞与过敏性鼻炎相关性分析

2020-04-23 AlexYang MedSci原创

持续气道正压通气(CPAP)治疗后发生的鼻塞会损害CPAP的依从性。过敏性鼻炎与接触非过敏性刺激患者的鼻塞有关。CPAP的使用也代表了可能的非过敏性刺激的存在(比如湿度、温度、压力和气流)。

持续气道正压通气(CPAP)治疗后发生的鼻塞会损害CPAP的依从性。过敏性鼻炎与接触非过敏性刺激患者的鼻塞有关。CPAP的使用也代表了可能的非过敏性刺激的存在(比如湿度、温度、压力和气流)。

最近,有研究人员比较了过敏性鼻炎、非过敏性鼻炎和没有鼻炎的CPAP使用者的鼻塞情况。研究是一个前瞻性的群体研究。研究共包括了102名参与者,其中61名(60%)为男性,平均(SD)的年龄为50(13)。研究包括了23名(22.5%)过敏性鼻炎参与者,67名(65.7%)非过敏性鼻炎参与者和12名(11.8%)没有鼻炎的参与者。在整个群体中,鼻塞从基线到第3个月均有所改善(平均(SD)NOSE评分,38(26)到27(23),平均(SD)变化,-10 [23];95%CI,-15到-6;平均(SD)VAS评分,41 (27)到32 (28);平均(SD)变化, -10 (26);95% CI, (-15到-4))。与基线相比(NOSE评分14(1到28)和VAS评分15(95%CI ,0到30)),第3个月调整后鼻塞改善在过敏性鼻炎组中要比没有鼻炎组显著更少。

最后,研究人员指出,CPAP与鼻塞改善有关,但是在患有过敏性鼻炎的患者中改善较少。基线过敏性鼻炎能够预测那些患者对CPAP造成的鼻塞更敏感。

原始出处:

Skirko JR, James KT, Shusterman DJ et al. Association of Allergic Rhinitis With Change in Nasal Congestion in New Continuous Positive Airway Pressure Users. JAMA Otolaryngol Head Neck Surg. 09 April 2020.

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2047249, encodeId=4fdd204e24950, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Mon May 11 07:32:03 CST 2020, time=2020-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837819, encodeId=4a63183e81949, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Fri Aug 07 10:32:03 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044130, encodeId=62ec20441306a, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Oct 06 05:32:03 CST 2020, time=2020-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382246, encodeId=63a63822461f, content=这个群体应该比较少见, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=15935320972, createdName=148aac5dm62(暂无昵称), createdTime=Mon Apr 27 08:13:21 CST 2020, time=2020-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361144, encodeId=8c2713611446a, content=<a href='/topic/show?id=3e891034351c' target=_blank style='color:#2F92EE;'>#鼻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103435, encryptionId=3e891034351c, topicName=鼻塞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Sat Apr 25 04:32:03 CST 2020, time=2020-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523643, encodeId=b356152364365, content=<a href='/topic/show?id=f6f1e2533e3' target=_blank style='color:#2F92EE;'>#相关性分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72533, encryptionId=f6f1e2533e3, topicName=相关性分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad8f11536374, createdName=anminleiryan, createdTime=Sat Apr 25 04:32:03 CST 2020, time=2020-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036064, encodeId=f68b103606462, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Thu Apr 23 16:32:03 CST 2020, time=2020-04-23, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2047249, encodeId=4fdd204e24950, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Mon May 11 07:32:03 CST 2020, time=2020-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837819, encodeId=4a63183e81949, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Fri Aug 07 10:32:03 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044130, encodeId=62ec20441306a, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Oct 06 05:32:03 CST 2020, time=2020-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382246, encodeId=63a63822461f, content=这个群体应该比较少见, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=15935320972, createdName=148aac5dm62(暂无昵称), createdTime=Mon Apr 27 08:13:21 CST 2020, time=2020-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361144, encodeId=8c2713611446a, content=<a href='/topic/show?id=3e891034351c' target=_blank style='color:#2F92EE;'>#鼻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103435, encryptionId=3e891034351c, topicName=鼻塞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Sat Apr 25 04:32:03 CST 2020, time=2020-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523643, encodeId=b356152364365, content=<a href='/topic/show?id=f6f1e2533e3' target=_blank style='color:#2F92EE;'>#相关性分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72533, encryptionId=f6f1e2533e3, topicName=相关性分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad8f11536374, createdName=anminleiryan, createdTime=Sat Apr 25 04:32:03 CST 2020, time=2020-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036064, encodeId=f68b103606462, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Thu Apr 23 16:32:03 CST 2020, time=2020-04-23, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2047249, encodeId=4fdd204e24950, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Mon May 11 07:32:03 CST 2020, time=2020-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837819, encodeId=4a63183e81949, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Fri Aug 07 10:32:03 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044130, encodeId=62ec20441306a, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Oct 06 05:32:03 CST 2020, time=2020-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382246, encodeId=63a63822461f, content=这个群体应该比较少见, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=15935320972, createdName=148aac5dm62(暂无昵称), createdTime=Mon Apr 27 08:13:21 CST 2020, time=2020-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361144, encodeId=8c2713611446a, content=<a href='/topic/show?id=3e891034351c' target=_blank style='color:#2F92EE;'>#鼻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103435, encryptionId=3e891034351c, topicName=鼻塞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Sat Apr 25 04:32:03 CST 2020, time=2020-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523643, encodeId=b356152364365, content=<a href='/topic/show?id=f6f1e2533e3' target=_blank style='color:#2F92EE;'>#相关性分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72533, encryptionId=f6f1e2533e3, topicName=相关性分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad8f11536374, createdName=anminleiryan, createdTime=Sat Apr 25 04:32:03 CST 2020, time=2020-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036064, encodeId=f68b103606462, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Thu Apr 23 16:32:03 CST 2020, time=2020-04-23, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2047249, encodeId=4fdd204e24950, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Mon May 11 07:32:03 CST 2020, time=2020-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837819, encodeId=4a63183e81949, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Fri Aug 07 10:32:03 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044130, encodeId=62ec20441306a, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Oct 06 05:32:03 CST 2020, time=2020-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382246, encodeId=63a63822461f, content=这个群体应该比较少见, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=15935320972, createdName=148aac5dm62(暂无昵称), createdTime=Mon Apr 27 08:13:21 CST 2020, time=2020-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361144, encodeId=8c2713611446a, content=<a href='/topic/show?id=3e891034351c' target=_blank style='color:#2F92EE;'>#鼻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103435, encryptionId=3e891034351c, topicName=鼻塞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Sat Apr 25 04:32:03 CST 2020, time=2020-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523643, encodeId=b356152364365, content=<a href='/topic/show?id=f6f1e2533e3' target=_blank style='color:#2F92EE;'>#相关性分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72533, encryptionId=f6f1e2533e3, topicName=相关性分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad8f11536374, createdName=anminleiryan, createdTime=Sat Apr 25 04:32:03 CST 2020, time=2020-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036064, encodeId=f68b103606462, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Thu Apr 23 16:32:03 CST 2020, time=2020-04-23, status=1, ipAttribution=)]
    2020-04-27 148aac5dm62(暂无昵称)

    这个群体应该比较少见

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2047249, encodeId=4fdd204e24950, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Mon May 11 07:32:03 CST 2020, time=2020-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837819, encodeId=4a63183e81949, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Fri Aug 07 10:32:03 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044130, encodeId=62ec20441306a, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Oct 06 05:32:03 CST 2020, time=2020-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382246, encodeId=63a63822461f, content=这个群体应该比较少见, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=15935320972, createdName=148aac5dm62(暂无昵称), createdTime=Mon Apr 27 08:13:21 CST 2020, time=2020-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361144, encodeId=8c2713611446a, content=<a href='/topic/show?id=3e891034351c' target=_blank style='color:#2F92EE;'>#鼻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103435, encryptionId=3e891034351c, topicName=鼻塞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Sat Apr 25 04:32:03 CST 2020, time=2020-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523643, encodeId=b356152364365, content=<a href='/topic/show?id=f6f1e2533e3' target=_blank style='color:#2F92EE;'>#相关性分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72533, encryptionId=f6f1e2533e3, topicName=相关性分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad8f11536374, createdName=anminleiryan, createdTime=Sat Apr 25 04:32:03 CST 2020, time=2020-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036064, encodeId=f68b103606462, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Thu Apr 23 16:32:03 CST 2020, time=2020-04-23, status=1, ipAttribution=)]
    2020-04-25 liuhuangbo
  6. [GetPortalCommentsPageByObjectIdResponse(id=2047249, encodeId=4fdd204e24950, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Mon May 11 07:32:03 CST 2020, time=2020-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837819, encodeId=4a63183e81949, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Fri Aug 07 10:32:03 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044130, encodeId=62ec20441306a, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Oct 06 05:32:03 CST 2020, time=2020-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382246, encodeId=63a63822461f, content=这个群体应该比较少见, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=15935320972, createdName=148aac5dm62(暂无昵称), createdTime=Mon Apr 27 08:13:21 CST 2020, time=2020-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361144, encodeId=8c2713611446a, content=<a href='/topic/show?id=3e891034351c' target=_blank style='color:#2F92EE;'>#鼻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103435, encryptionId=3e891034351c, topicName=鼻塞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Sat Apr 25 04:32:03 CST 2020, time=2020-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523643, encodeId=b356152364365, content=<a href='/topic/show?id=f6f1e2533e3' target=_blank style='color:#2F92EE;'>#相关性分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72533, encryptionId=f6f1e2533e3, topicName=相关性分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad8f11536374, createdName=anminleiryan, createdTime=Sat Apr 25 04:32:03 CST 2020, time=2020-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036064, encodeId=f68b103606462, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Thu Apr 23 16:32:03 CST 2020, time=2020-04-23, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=2047249, encodeId=4fdd204e24950, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Mon May 11 07:32:03 CST 2020, time=2020-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837819, encodeId=4a63183e81949, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Fri Aug 07 10:32:03 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044130, encodeId=62ec20441306a, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Oct 06 05:32:03 CST 2020, time=2020-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382246, encodeId=63a63822461f, content=这个群体应该比较少见, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=15935320972, createdName=148aac5dm62(暂无昵称), createdTime=Mon Apr 27 08:13:21 CST 2020, time=2020-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361144, encodeId=8c2713611446a, content=<a href='/topic/show?id=3e891034351c' target=_blank style='color:#2F92EE;'>#鼻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103435, encryptionId=3e891034351c, topicName=鼻塞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Sat Apr 25 04:32:03 CST 2020, time=2020-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523643, encodeId=b356152364365, content=<a href='/topic/show?id=f6f1e2533e3' target=_blank style='color:#2F92EE;'>#相关性分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72533, encryptionId=f6f1e2533e3, topicName=相关性分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad8f11536374, createdName=anminleiryan, createdTime=Sat Apr 25 04:32:03 CST 2020, time=2020-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036064, encodeId=f68b103606462, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Thu Apr 23 16:32:03 CST 2020, time=2020-04-23, status=1, ipAttribution=)]
    2020-04-23 旺医

    顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息

    0

相关资讯

Clin Otolaryngol:室内空气净化在治疗青蒿花粉过敏性鼻炎中的效果分析

最近,有研究人员评估了高效空气净化器对过敏性鼻炎的临床效果情况。研究人员进行了一个随机、双盲和临床控制试验,包括了激活的未激活的空气净化器版本。他们的研究包括了对青蒿花粉过敏的过敏性鼻炎患者,并在晚上使用空气过滤处理室内环境,之后在青蒿花粉撒播的季节在陕西榆林市评估了室内空气净化的临床效果。研究总共包括了90名患有过敏性鼻炎且对青蒿花粉过敏的患者,并随机分成数目相同的两个小组。研究的主要饥饿过为视

Dig Liver Dis: 慢性中性粒细胞性非过敏性鼻炎与胃食管反流病的酸暴露时间增加有关

慢性鼻炎是一种流行性疾病,可分为过敏性(AR)和非过敏性鼻炎(NAR)。鼻细胞学可以根据炎性细胞浸润情况识别不同的NAR亚型。

Front Pharmacol:大籽蒿花粉过敏性鼻炎1年皮下免疫治疗临床效果评估

皮下免疫治疗是改善过敏性鼻炎的唯一方法,并能够在药物中断后维持长期的治疗结果。代谢组在过敏性疾病的研究中应用越来越多,包括了过敏性鼻炎。然而,能够评估临床效果和大籽蒿(Artemisia siever

Am J Otolaryngol:后鼻神经切除术对过敏性鼻炎的抑制作用研究

最近的指南阐释了过敏性鼻炎(AR)影响生活质量。神经肽在AR中具有核心的作用。最近,有研究人员确定了后鼻神经切除(PNN)对治疗AR的效果情况以及抑制神经肽和2型细胞因子表达的情况。

Clin Transl Allergy:鼻灌洗对儿童过敏性鼻炎的控制

鼻灌洗(NI)越来越成为过敏性鼻炎(AR)的一种非处方辅助治疗方法,但是其临床效果相关研究有限。

Allergy:过敏性鼻炎中CD23的表达建立T-B细胞互作

B细胞亚群和T-B细胞互作对过敏性鼻炎的贡献以及过敏原免疫治疗(AIT)的机制仍旧了解甚少。最近,有研究人员在AR患者中探究了循环B细胞特征、潜在机制和与AIT临床响应相关性。